DeepVessel Plaque
Coronary plaque quantification and characterization
Key Facts
About Keya Medical
Keya Medical is a commercial-stage AI diagnostics company focused on revolutionizing the assessment of coronary artery disease. Its core technology, DEEPVESSEL FFR, provides a non-invasive, AI-powered physiological analysis (FFRCT) from standard coronary CT angiography (CCTA) scans, helping clinicians determine if a patient requires invasive intervention. The company has achieved significant regulatory milestones, including FDA clearance (2022), CE Mark (2018), and NMPA approval in China (2020), and is benefiting from the establishment of a new Category I CPT code (75580) in the U.S. for FFRCT analysis. Keya Medical operates globally, with its software available in the USA, EMEA, China, and Singapore, positioning it at the intersection of the rapidly growing AI healthcare and cardiovascular diagnostics markets.
View full company profile